Moderators

Lung Cancer FAQ: I have advanced NSCLC and have been told I don't have an EGFR mutation. Does this mean I won't benefit from an EGFR inhibitor?
Post

There is no question that the recognition of an activating mutation in the gene for the epidermal growth factor receptor (EGFR) has revolutionized our understanding of why some patients with advanced/metastatic NSCLC develop a profound benefit from the class of oral EGFR tyrosine kinase inhibitors (TKIs).

Lung Cancer FAQ: I've just been diagnosed with advanced NSCLC. What treatment should I be starting with??
Post

The initial or "first line" management of advanced NSCLC has evolved quite a bit over the past 10 years, in that time moving from a much more uniform approach of very similar treatment for just about everyone to a revised approach that is far more individualized. First, we assess key issues like the subtype of NSCLC, focusing largely on whether it is squamous cell or non-squamous NSCLC, because treatment tends to diverge very early based on this factor.

Comments

test
Post Date:
Original Post: Nodule concern

test test test

test
Post Date:
Original Post: Test - forum post

test

Example Comment for Forum Post
Post Date:
Original Post: SCLC Example Post

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam id sapien quis lorem sollicitudin